Research dossier
Clinical research on Vitamin K
8 trials reviewed across 4 indications.
Strongest evidence
Blood clotting and prevention of bleeding
Mechanism
Vitamin K1 (phylloquinone) is the cofactor for gamma-glutamyl carboxylation of factors II, VII, IX, and X — the clotting cascade. Without vitamin K, these proteins cannot bind calcium and clotting fails. This is what newborns get the routine vitamin K shot for.
The one universally accepted role for vitamin K. Frank deficiency causes bleeding; routine vitamin K1 administration to newborns prevents hemorrhagic disease of the newborn. Adults rarely become deficient unless on broad-spectrum antibiotics or with malabsorption.
Routine in newborns. Adults on warfarin must keep K1 intake consistent — sudden changes in green-leafy intake destabilize INR.
Bone mineral density and fractures
Mechanism
Vitamin K activates osteocalcin, the bone matrix protein responsible for binding calcium to hydroxyapatite. Carboxylated osteocalcin levels respond strongly to K2 dosing.
The mechanism is real. The trial evidence is weaker than supplement marketing implies. The largest positive trial was industry-funded, the high-dose Japanese MK-4 trials were open-label, and recent independent meta-analysis showed no significant fracture reduction.
May be reasonable as adjunct in postmenopausal women already on calcium and vitamin D, but should not replace bisphosphonate or other proven osteoporosis therapy.
Knapen MK-7 — bone loss in postmenopausal women
positive · RCT
Knapen et al., 2013, Osteoporosis International (PMID 23525894)n=244Industry-fundedThree-year trial of 180 µg/day MK-7 in postmenopausal women. Modest preservation of vertebral and femoral neck bone density vs placebo. Often cited as the headline trial for K2 and bone.
Funded by NattoPharma, the dominant commercial supplier of MK-7. The principal investigators have ongoing relationships with the manufacturer. The independent replication record is thin.
Shiraki MK-4 — vertebral fracture in osteoporosis
positive · RCT
Shiraki et al., 2000, Journal of Bone and Mineral Research (PMID 10750566)n=241Open-label trial in Japanese women with established osteoporosis. High-dose pharmaceutical MK-4 reduced incident vertebral fractures vs no treatment. Drove the inclusion of menatetrenone in Japanese osteoporosis guidelines.
Open-label, not blinded — patients knew their assignment, which inflates measured benefit. Pharmaceutical 45 mg dose is roughly 250x typical supplement doses. Findings have not replicated cleanly in non-Japanese populations.
Cockayne meta-analysis — vitamin K and fractures
mixed · Meta-analysis
Cockayne et al., 2006, Archives of Internal Medicine (PMID 16801507)n=6759Pooled trials suggested reduced vertebral and hip fractures with vitamin K, but the effect was driven heavily by Japanese MK-4 trials including Shiraki 2000. Western trials and trials with Western dosing showed weaker effects.
Older meta-analysis dominated by open-label Japanese pharmaceutical-dose trials. Has not been replicated by the larger, more rigorous independent trials of the last decade.
Ma & Huang meta-analysis — K2 and bone in postmenopausal women
mixed · Meta-analysis
Ma et al., 2022, Frontiers in Endocrinology (PMID 36033779)n=1300Pooled K2 trials in postmenopausal women showed modest benefit on lumbar BMD but no statistically significant reduction in fractures. Effect size shrinks once high-dose Japanese MK-4 trials are excluded.
Most evidence is from small and/or industry-related trials. Removing Japanese pharmaceutical-dose MK-4 trials further weakens the bone effect. Fracture endpoint, the only one that matters clinically, was non-significant.
Arterial calcification and cardiovascular disease
Mechanism
Vitamin K activates matrix Gla protein (MGP), a potent inhibitor of arterial calcification. Inactive MGP rises in vitamin K insufficiency and correlates with arterial calcification — the mechanistic story is compelling.
The mechanism is one of the strongest in nutrition. The clinical-trial outcomes are not. Two independent randomized trials (AVADEC 2022 in aortic valve calcification, TreVasc-HDK 2023 in dialysis) both failed to slow CT-measured calcification with high-dose MK-7. The mechanism is real; the clinical translation has not held up.
Routine K2 supplementation for cardiovascular prevention is not supported by independent randomized trials at meaningful endpoints.
Knapen MK-7 — arterial stiffness in postmenopausal women
positive · RCT
Knapen et al., 2015, Thrombosis and Haemostasis (PMID 25694037)n=244Industry-fundedCompanion analysis to the bone trial. MK-7 reduced carotid arterial stiffness in postmenopausal women over three years. Foundational citation for the K2 cardiovascular hypothesis.
Same NattoPharma funding stream. Surrogate marker (arterial stiffness), not hard cardiovascular outcomes. The two later independent trials (Diederichsen, TreVasc-HDK) tested actual calcification and were null.
Brandenburg — vitamin K1 and aortic valve calcification
positive · RCT
Brandenburg et al., 2017, Circulationn=99Small trial of vitamin K1 in adults with aortic valve calcification. Showed slowing of CT-measured calcification vs placebo over one year. Generated enthusiasm for the calcification hypothesis.
Small (n=99), single-center, surrogate endpoint (CT calcification progression, not clinical events). The two larger trials that followed (Diederichsen 2022, TreVasc-HDK 2023) were null.
AVADEC — vitamin K2 + vitamin D for aortic valve calcification
Null · RCT
Diederichsen et al., 2022, Circulation (PMID 35465686)n=365Larger and more rigorous than Brandenburg. Two years of high-dose MK-7 with vitamin D in men with aortic valve calcification. No reduction in calcification progression on CT vs placebo. Independent funding.
One of the two key independent trials that undercut the K2 calcification narrative. Population was older men with established calcification — may not generalize to primary prevention.
TreVasc-HDK — high-dose K2 for coronary artery calcification in dialysis
Null · RCT
Mok et al., 2023, Journal of the American Society of Nephrology (PMID 37705910)n=250High-dose MK-7 in dialysis patients — the population with the most florid vascular calcification and the strongest mechanistic case for benefit. No reduction in coronary artery calcification progression vs placebo over 18 months.
If MK-7 was going to slow calcification anywhere, it should have shown it here. Independent funding. Closes the door on the dialysis calcification hypothesis at this dose.
Dental and oral calcification
Mechanism
Matrix Gla protein and osteocalcin are also expressed in dental tissues, suggesting a role for vitamin K in dentin and enamel mineralization.
Mechanism is plausible by extension from bone biology. There are no rigorous human trials with dental endpoints to support oral-health claims.
Marketing claim, not clinical claim. There is no trial evidence supporting K2 specifically for dental health in humans.
3 forms of Vitamin K compared
Vitamin K1 (phylloquinone)
Absorbed primarily in the small intestine with dietary fat
Best forCoagulation, dietary reference form, newborn injection to prevent bleedingThe form found in green leafy vegetables and the form your body uses for clotting. Half-life of a few hours in plasma. This is the form that interacts with warfarin.
Vitamin K2 MK-4 (menatetrenone)
Short plasma half-life of approximately 1 hour. Japanese trials used 45 mg/day pharmaceutical dosing.
Best forPharmaceutical osteoporosis treatment in JapanBody can convert K1 to MK-4 in some tissues. The 45 mg/day dose used in Japanese trials is roughly 250x typical supplement doses. Most Western K2 supplements use MK-7 instead because MK-4's short half-life requires multiple daily doses.
Vitamin K2 MK-7
Long plasma half-life of approximately 3 days, allowing once-daily dosing
Best forModern bone and arterial-calcification supplementsSourced from natto fermentation or synthetic. Typical supplement dose is 90–180 µg/day. The bulk of K2 marketing is built on MK-7. Independent trials of MK-7 for cardiovascular calcification have been null.
Are you deficient? Symptoms, risk groups, lab tests
Frank vitamin K1 deficiency is rare in healthy adults eating any green vegetables. Functional insufficiency — defined by elevated undercarboxylated osteocalcin or matrix Gla protein — is more common, particularly in older adults and people on broad-spectrum antibiotics, but its clinical significance outside the bone and vessel context is debated.
Common symptoms
- Easy bruising
- Bleeding from gums or nose
- Heavy menstrual bleeding
- Blood in urine or stool
- Prolonged bleeding from minor cuts
- Hemorrhagic disease of the newborn — bleeding in the first weeks of life in unsupplemented infants
- Elevated undercarboxylated osteocalcin (subclinical, lab-only)
- Elevated inactive matrix Gla protein (subclinical, lab-only)
Who is at risk
Newborns, especially exclusively breastfed
Vitamin K crosses the placenta poorly and breast milk is low in K1. The routine intramuscular vitamin K shot at birth prevents hemorrhagic disease of the newborn — refusing it carries real bleeding risk.
e.g. cefoperazone, moxalactam, long courses of any broad-spectrum antibiotic
Adults on long-term broad-spectrum antibiotics
Gut bacteria contribute meaningfully to vitamin K2 stores. Sustained antibiotic use suppresses these bacteria, lowering vitamin K availability.
Adults with fat malabsorption
Vitamin K is fat-soluble. Cystic fibrosis, chronic pancreatitis, celiac disease, Crohn's, and bariatric surgery all impair absorption.
Adults with chronic liver disease
The liver synthesizes the clotting factors that vitamin K activates. Severe liver disease produces a functional vitamin K-resistant coagulopathy.
Adults on warfarin
Warfarin works by blocking vitamin K recycling, deliberately inducing a functional deficiency to prevent clotting. This is therapeutic, not pathological — but adding vitamin K supplements undoes the medication.
Older adults with low green-vegetable intake
K1 intake correlates strongly with leafy green consumption. Older adults with limited diets and reduced gut bacterial diversity may have lower functional K status.
Lab markers
Prothrombin time (PT) / INR
Standard clinical test of coagulation function. Insensitive to subclinical vitamin K insufficiency — only flags frank deficiency or warfarin-style impairment.
Better:Undercarboxylated osteocalcin (research-grade), Inactive matrix Gla protein dp-ucMGP (research-grade)
- Normal INR (off anticoagulants)
- 0.8–1.2
- Therapeutic INR on warfarin
- 2.0–3.0 for most indications
Side effects and drug interactions
Side effects
Reversal of anticoagulation
Severe · Any addition or sudden change in vitamin K intake while on warfarin
Vitamin K directly antagonizes warfarin. Even moderate K1 or K2 supplementation can drop INR out of therapeutic range and increase clotting risk in a warfarin patient.
GI upset
Uncommon
Mild stomach discomfort or changes in stool consistency, occasionally reported with high-dose K2 formulations.
Allergic reaction to injectable K1
Rare
Rare anaphylactoid reactions reported with intravenous phylloquinone administration. Not a concern with oral supplements.
Drug interactions
Reduces nutrient status
warfarin (Coumadin)Vitamin K is the direct biochemical antagonist of warfarin. Any vitamin K supplement, and any change in dietary vitamin K intake, will shift INR.
Do not start vitamin K supplements without telling your prescriber. Keep dietary green-vegetable intake roughly consistent rather than swinging high and low. The DOAC class (apixaban, rivaroxaban, dabigatran, edoxaban) does NOT interact with vitamin K.
Reduces nutrient status
bile acid sequestrants (cholestyramine, colestipol)orlistatmineral oilezetimibe (mild effect)These agents impair fat-soluble vitamin absorption, which can lower vitamin K uptake from food and supplements.
Separate vitamin K dosing from these drugs by at least 2 hours. Long-term users should discuss vitamin K status with their clinician.
Reduces nutrient status
broad-spectrum antibiotics (long courses)Gut bacteria contribute to vitamin K2 status. Long antibiotic courses reduce this contribution.
Short courses are not a concern. Sustained antibiotic use, especially in patients with limited dietary K1, can produce functional insufficiency.
Other critical caveats
- Never start vitamin K supplementation while on warfarin without your prescriber's approval. Vitamin K reverses warfarin and raises clotting risk. The DOAC anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban) do NOT interact with vitamin K.
- The two largest independent trials of high-dose MK-7 for arterial calcification (Diederichsen 2022, TreVasc-HDK 2023) were null. The cardiovascular case for routine K2 supplementation is much weaker than supplement marketing suggests.
- Most positive K2 trials are industry-funded or open-label Japanese pharmaceutical-dose studies. Apply skepticism to claims from these sources, particularly when independent replication is missing.
Frequently asked
Should I take vitamin K2 with my vitamin D?
The bundled D + K2 supplement is everywhere, and the marketing logic — vitamin D drives calcium absorption, K2 directs it into bone rather than arteries — sounds compelling. The trials don't carry it. The two best independent trials (Diederichsen 2022, TreVasc-HDK 2023) showed no benefit on arterial calcification. There's no evidence that adding K2 to vitamin D improves cardiovascular outcomes. If you eat any green vegetables you're getting K1; the bundling is largely a price-up move.What's the difference between K1, MK-4, and MK-7?
K1 (phylloquinone) is in green leafy vegetables and runs the clotting cascade. MK-4 has a short plasma half-life of about an hour and was used at 45 mg/day in Japanese pharmaceutical osteoporosis trials. MK-7 has a long half-life of about three days, comes from natto or synthesis, and is the form in most modern Western supplements at 90–180 µg/day. The independent cardiovascular trials of MK-7 were null.Can I take vitamin K if I'm on a blood thinner?
Depends on which thinner. Warfarin: do not start vitamin K without your prescriber's approval. Vitamin K reverses warfarin and shifts your INR. The newer DOAC anticoagulants — apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Savaysa) — do NOT interact with vitamin K and are unaffected by it.Will vitamin K2 prevent osteoporosis?
Modest, conditional, mostly marketing-grade evidence. The headline MK-7 bone trial (Knapen 2013) was funded by the dominant MK-7 supplier. Japanese MK-4 osteoporosis trials used pharmaceutical 45 mg/day doses, were mostly open-label, and have not replicated cleanly outside Japan. Pooled analysis shows no significant fracture reduction. K2 is a reasonable adjunct but is not a substitute for proven osteoporosis therapy.Is it safe to take vitamin K long-term?
Vitamin K has no Tolerable Upper Intake Level set by the IOM — there is no clearly established toxicity in healthy adults at doses used in supplements. The main long-term concern is the warfarin interaction. If you start or stop a vitamin K supplement, tell your clinician so anticoagulation status can be checked.
References
- 01NIH Office of Dietary Supplements — Vitamin K Health Professional Fact Sheet
- 02StatPearls — Vitamin K Deficiency (NCBI Bookshelf)
Last reviewed2026-05-07